AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10458528 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment
Number of subjects: 30
Study 7597270 — intervention group
Group type: COMPARATOR
Intervention: Lateral body position (right and left lateral decubitus)
Number of subjects: 30
Study 1693316 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ifosfamide, cisplatin, and bleomycin (BIP) prior to radiotherapy
Number of subjects: 66
Study 1693316 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 66
Study 38704 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (Group I)
Number of subjects: 25
Study 38704 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanalgesia (Group II)
Number of subjects: 25
Study 38704 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 25
Study 6749634 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid for dissolution of gallstones
Number of subjects: 22
Study 6749634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing chenotherapy
Number of subjects: 22
Study 6749634 — intervention group
Group type: EXPERIMENTAL
Intervention: Choleitholytic therapy
Number of subjects: 22
Study 30513347 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site bolus NGF injection (5 µg)
Number of subjects: 20
Study 30513347 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially distributed low-dose NGF injections (1 µg, 4 cm distance)
Number of subjects: 20
Study 30048048 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately rough implant (Sa: 1.3 μm)
Number of subjects: 21
Study 30048048 — intervention group
Group type: COMPARATOR
Intervention: Hybrid surface implant (moderately rough implant body [Sa: 1.3 μm] and minimally rough implant neck [Sa: 0.9 μm])
Number of subjects: 21
Study 26205305 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-based cognitive training (pb-CT) combined with reminiscence therapy (RT) for 3 months
Number of subjects: 348
Study 24254057 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley oil T3 (nanoemulsified)
Number of subjects: 100
Study 24254057 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil T3 (nanoemulsified)
Number of subjects: 100
Study 24254057 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley oil supplements
Number of subjects: 100
Study 24254057 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil supplements
Number of subjects: 100
Study 22851543 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular volume fraction (ECV) measured using gadolinium contrast in patients
Number of subjects: 802
Study 22851543 — intervention group
Group type: COMPARATOR
Intervention: Extracellular volume fraction (ECV) in healthy volunteers
Number of subjects: 802
Study 22851543 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular volume fraction (ECV) in patients
Number of subjects: 802
Study 20006641 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weights
Number of subjects: 108
Study 20006641 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tubing
Number of subjects: 108
Study 20006641 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 108
Study 17324686 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 49
Study 16286543 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (target dose, 400 mg/d in adults)
Number of subjects: 22
Study 16286543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12098088 — intervention group
Group type: EXPERIMENTAL
Intervention: Kogenate®
Number of subjects: 0
Study 12098088 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinate®
Number of subjects: 0
Study 12098088 — intervention group
Group type: EXPERIMENTAL
Intervention: ReFacto®
Number of subjects: 0
Study 12098088 — intervention group
Group type: EXPERIMENTAL
Intervention: Kogenate FS®
Number of subjects: 0
Study 10210384 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg furosemide
Number of subjects: 99
Study 10210384 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg furosemide on second visit
Number of subjects: 99
Study 10210384 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg furosemide on first visit
Number of subjects: 99
Study 10210384 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic use
Number of subjects: 99
Study 8572212 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms)
Number of subjects: 7
Study 8572212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2093379 — intervention group
Group type: EXPERIMENTAL
Intervention: New semiautomated algorithm to quantify Holter-detected myocardial ischemia
Number of subjects: 0
Study 2093379 — intervention group
Group type: COMPARATOR
Intervention: Simple measurements (number and duration of ischemic events)
Number of subjects: 0
Study 350497 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g salsalate per day
Number of subjects: 20
Study 350497 — intervention group
Group type: COMPARATOR
Intervention: 3.6 g soluble aspirin per day
Number of subjects: 20
Study 350497 — intervention group
Group type: EXPERIMENTAL
Intervention: salsalate
Number of subjects: 20
Study 350497 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 20
Study 31858128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program (food rations including corn-soy blend and micronutrient-fortified vegetable oil)
Number of subjects: 11906
Study 31858128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program
Number of subjects: 11906
Study 31858128 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprogram effects of Tubaramure program
Number of subjects: 11906
Study 31289313 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical biometer SS‐OCT scans
Number of subjects: 749
Study 31289313 — intervention group
Group type: COMPARATOR
Intervention: Conventional SD‐OCT
Number of subjects: 749
Study 28445871 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Integrity stents (n = 481)
Number of subjects: 957
Study 28445871 — intervention group
Group type: EXPERIMENTAL
Intervention: Promus Element stents (n = 476)
Number of subjects: 957
Study 28445871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 957
Study 25916341 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 15411
Study 25916341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15411
Study 23850262 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Lipoprotein-B (Lp-B)
Number of subjects: 436
Study 23850262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp-B:C
Number of subjects: 436
Study 23850262 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (ApoB)
Number of subjects: 436
Study 23850262 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo-AII
Number of subjects: 436
Study 23850262 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoC-III
Number of subjects: 436
Study 23850262 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoC-III in VLDL (heparin-manganese precipitate)
Number of subjects: 436
Study 23850262 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoC-III in HDL (heparin-manganese supernatant)
Number of subjects: 436
Study 20625344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound-activated light device present (turned on)
Number of subjects: 0
Study 20625344 — intervention group
Group type: COMPARATOR
Intervention: Sound-activated light device present (turned off)
Number of subjects: 0
Study 20625344 — intervention group
Group type: COMPARATOR
Intervention: No device present
Number of subjects: 0
Study 19060001 — intervention group
Group type: EXPERIMENTAL
Intervention: ASDAS (Ankylosing Spondylitis Disease Activity Score)
Number of subjects: 2
Study 19060001 — intervention group
Group type: COMPARATOR
Intervention: BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Number of subjects: 2
Study 19060001 — intervention group
Group type: EXPERIMENTAL
Intervention: ASDAS version including back pain, duration of morning stiffness, patient global assessment, peripheral joint complaints and CRP
Number of subjects: 2
Study 17241101 — intervention group
Group type: COMPARATOR
Intervention: Inhaled β2-agonists (formoterol, salbutamol, salmeterol, terbutaline)
Number of subjects: 19
Study 17241101 — intervention group
Group type: COMPARATOR
Intervention: Supratherapeutic doses of salbutamol (800-1200μg)
Number of subjects: 19
Study 17241101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of salbutamol
Number of subjects: 19
Study 15570242 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH, 450 IU/kg/24 hr)
Number of subjects: 8
Study 15570242 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin, 100 IU/kg given twice at a 12-hr interval
Number of subjects: 8
Study 15570242 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin, 200 IU/kg given once
Number of subjects: 8
Study 15570242 — intervention group
Group type: COMPARATOR
Intervention: Saline-solution infusion
Number of subjects: 8
Study 12002786 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in calcium and exogenous microparticles
Number of subjects: 0
Study 10228904 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125 screening with a cutoff value of 30 U/mL
Number of subjects: 0
Study 10228904 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography as a second-line test
Number of subjects: 0
Study 10228904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical algorithm analyzing rates of change of CA 125
Number of subjects: 0
Study 10228904 — intervention group
Group type: COMPARATOR
Intervention: Screening strategies incorporating CA 125
Number of subjects: 0
Study 7611754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of Epi‐adriamycin 30‐40 mg/body and CDDP 100 mg/body via reservoir every two weeks post‐operatively (group R)
Number of subjects: 118
Study 7611754 — intervention group
Group type: EXPERIMENTAL
Intervention: One-shot infusion of Epi‐adriamycin or adriamycin (group O)
Number of subjects: 118
Study 7611754 — intervention group
Group type: COMPARATOR
Intervention: Control group (group N)
Number of subjects: 118
Study 2363531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 3 micrograms/kg
Number of subjects: 95
Study 2363531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg
Number of subjects: 95
Study 2363531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg
Number of subjects: 95
Study 380635 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-wear soft lenses
Number of subjects: 0
Study 30753368 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (HRV)
Number of subjects: 0
Study 30753368 — intervention group
Group type: COMPARATOR
Intervention: Control (no HRV)
Number of subjects: 0
Study 29976293 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-8 levels measured immediately after PCI and at day 1
Number of subjects: 258
Study 29976293 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-8 levels at day 1
Number of subjects: 258
Study 29976293 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 levels in the highest quartile measured at all sampling points
Number of subjects: 258
Study 27374016 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercises
Number of subjects: 216
Study 27374016 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercises with behavioral approach
Number of subjects: 216
Study 27374016 — intervention group
Group type: COMPARATOR
Intervention: General physical activity
Number of subjects: 216
Study 23981528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics
Number of subjects: 56
Study 23981528 — intervention group
Group type: COMPARATOR
Intervention: Topical mydriatics
Number of subjects: 56
Study 21642470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 30
Study 21642470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 100 mg
Number of subjects: 30
Study 21642470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg with Ketoconazole 400 mg
Number of subjects: 30
Study 21642470 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 30
Study 21642470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19473072 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program with low-level laser therapy (LLLT); 904-nm Ga-As laser in continuous mode, power density 130 mW/cm², dose 0.585 J/point.
Number of subjects: 50
Study 19473072 — intervention group
Group type: COMPARATOR
Intervention: Exercise program with polarized polychromatic non-coherent light (Bioptron 2); administered perpendicularly to the lateral epicondyle at three points for 6 min at each position.
Number of subjects: 50
Study 17768457 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated vasodilation (FMD)
Number of subjects: 92
Study 17768457 — intervention group
Group type: COMPARATOR
Intervention: Typical anginal chest pain
Number of subjects: 92
Study 17768457 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 92
Study 17768457 — intervention group
Group type: COMPARATOR
Intervention: Myocardial perfusion imaging (MPI)
Number of subjects: 92
Study 15345790 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 60
Study 15345790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11136139 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg etomidate
Number of subjects: 31
Study 11136139 — intervention group
Group type: COMPARATOR
Intervention: 0.05‐0.1 mg/kg midazolam (control group)
Number of subjects: 31
Study 9633671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (tryptophan-free amino acid beverage plus amino acid capsules)
Number of subjects: 16
Study 9633671 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine depletion (alpha-methyl-paratyrosine)
Number of subjects: 16
Study 9633671 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion (Diphenhydramine hydrochloride)
Number of subjects: 16
Study 7935995 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan treatment
Number of subjects: 28
Study 7935995 — intervention group
Group type: EXPERIMENTAL
Intervention: Blast crisis phase
Number of subjects: 28
Study 7935995 — intervention group
Group type: COMPARATOR
Intervention: Initial phase at diagnosis
Number of subjects: 28
Study 7935995 — intervention group
Group type: COMPARATOR
Intervention: Remission phase
Number of subjects: 28
Study 7935995 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between red cell ferritin and hemoglobin (Hb)
Number of subjects: 28
Study 7935995 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission after busulphan treatment
Number of subjects: 28
Study 3346570 — intervention group
Group type: EXPERIMENTAL
Intervention: Q fever vaccine
Number of subjects: 13
Study 28692567 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward digit span training for 5 weeks
Number of subjects: 44
Study 28692567 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward digit span training for 5 weeks
Number of subjects: 44
Study 28692567 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 44
Study 28692567 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison with children with normal hearing
Number of subjects: 44
Study 26993648 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-dyed liquids
Number of subjects: 40
Study 26993648 — intervention group
Group type: COMPARATOR
Intervention: Non-dyed liquids
Number of subjects: 40
Study 26993648 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volumes of thin liquids (90 ml)
Number of subjects: 40
Study 24229481 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized psychodynamic therapy (PDT)
Number of subjects: 66
Study 24229481 — intervention group
Group type: COMPARATOR
Intervention: Waiting list/treatment-as-usual (WL/TAU)
Number of subjects: 66
Study 23537708 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide in combination with low-dose CAG (E-CAG)
Number of subjects: 228
Study 23537708 — intervention group
Group type: COMPARATOR
Intervention: CAG without etoposide (CAG)
Number of subjects: 228
Study 23537708 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CR who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 228
Study 23537708 — intervention group
Group type: COMPARATOR
Intervention: Patients without allo-HSCT
Number of subjects: 228
Study 20959071 — intervention group
Group type: EXPERIMENTAL
Intervention: Filling-fat group
Number of subjects: 60
Study 20959071 — intervention group
Group type: COMPARATOR
Intervention: Non-filling-fat group
Number of subjects: 60
Study 18188694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg/day plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle
Number of subjects: 399
Study 18188694 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 2,500 mg/m2 on the same schedule
Number of subjects: 399
Study 18188694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 399
Study 16896785 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 50
Study 16896785 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-atorvastatin (10 mg + 20 mg)
Number of subjects: 50
Study 14652260 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructing speed bumps
Number of subjects: 723
Study 14652260 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteering as a crossing guard
Number of subjects: 723
Study 14652260 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending a neighbourhood meeting
Number of subjects: 723
Study 14652260 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending a safety workshop
Number of subjects: 723
Study 10992375 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter replacement before antimicrobial therapy
Number of subjects: 54
Study 10992375 — intervention group
Group type: COMPARATOR
Intervention: No catheter replacement before antimicrobial therapy
Number of subjects: 54
Study 9463121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulfrich's pendulum test
Number of subjects: 39
Study 7514237 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mortality
Number of subjects: 2000
Study 7514237 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to death, progression to severe/resistant heart failure, reinfarction or stroke
Number of subjects: 2000
Study 7514237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization and mode of death
Number of subjects: 2000
Study 3080269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 6
Study 3080269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Ethanol
Number of subjects: 6
Study 3080269 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 6
Study 29447782 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 172
Study 29447782 — intervention group
Group type: COMPARATOR
Intervention: Second-generation everolimus-eluting stent (DES)
Number of subjects: 172
Study 27323447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique needling combined with Tuina (Acu+ Tuina)
Number of subjects: 120
Study 25042422 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive scapular strengthening exercises for 12 weeks
Number of subjects: 59
Study 25042422 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 59
Study 24195623 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Lactobacillus gasseri OLL2809
Number of subjects: 44
Study 24195623 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Lactobacillus gasseri OLL2809 + 900 mg α-lactalbumin
Number of subjects: 44
Study 24195623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 21824504 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 88
Study 21824504 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 88
Study 21824504 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of caffeinated coffee
Number of subjects: 88
Study 21824504 — intervention group
Group type: COMPARATOR
Intervention: Expectation of decaffeinated coffee
Number of subjects: 88
Study 21824504 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (both actual and expected)
Number of subjects: 88
Study 18460201 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme (cognitive-behavioural, manual based)
Number of subjects: 140
Study 18460201 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme
Number of subjects: 140
Study 18460201 — intervention group
Group type: COMPARATOR
Intervention: Information only control procedure
Number of subjects: 140
Study 16762862 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at Baihui(DU20), Shuigou(DU26) and Shenmen(HT7)
Number of subjects: 10
Study 16762862 — intervention group
Group type: COMPARATOR
Intervention: Routine acupoints for hemiplegia (control group)
Number of subjects: 10
Study 12663512 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit supplementation (specific dosage not mentioned) for 3-week periods
Number of subjects: 0
Study 12663512 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit supplementation (specific dosage not mentioned)
Number of subjects: 0
Study 10887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of genetically modified CD8(+) T cells (10(10) cells)
Number of subjects: 2
Study 10887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Second series of infusions of both CD4(+) and CD8(+) T cells engineered to express the chimeric receptor, costimulated ex vivo with beads coated with anti‐CD3 and anti‐CD28
Number of subjects: 2
Study 10887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of genetically modified HIV‐antigen‐specific T cells
Number of subjects: 2
Study 10887107 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of modified CD4(+) and CD8(+) T cells together after ex vivo costimulation
Number of subjects: 2